JP2012506381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506381A5 JP2012506381A5 JP2011532324A JP2011532324A JP2012506381A5 JP 2012506381 A5 JP2012506381 A5 JP 2012506381A5 JP 2011532324 A JP2011532324 A JP 2011532324A JP 2011532324 A JP2011532324 A JP 2011532324A JP 2012506381 A5 JP2012506381 A5 JP 2012506381A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- pharmaceutically acceptable
- acceptable salt
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 20
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- -1 pyrazol-4-yl ring Chemical group 0.000 claims description 6
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 2
- 125000002723 alicyclic group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 0 CCOc(c(F)c1F)ccc1N(C(c1cc(-c2cc(C)cc(C)c2)cnc1N)=N*)N Chemical compound CCOc(c(F)c1F)ccc1N(C(c1cc(-c2cc(C)cc(C)c2)cnc1N)=N*)N 0.000 description 13
- VQJSFMZETQLCGE-KGZUQBBUSA-N C=C(/C(/c1nnn[n]1-c(c(F)c1F)ccc1O)=C\C(\c1cc2ccccc2[s]1)=C/N)N Chemical compound C=C(/C(/c1nnn[n]1-c(c(F)c1F)ccc1O)=C\C(\c1cc2ccccc2[s]1)=C/N)N VQJSFMZETQLCGE-KGZUQBBUSA-N 0.000 description 1
- AQADTUPPIIFUNQ-UHFFFAOYSA-N CC(C)CC[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OC(CC3)CCC3N(C)C)cnc2N)c1 Chemical compound CC(C)CC[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OC(CC3)CCC3N(C)C)cnc2N)c1 AQADTUPPIIFUNQ-UHFFFAOYSA-N 0.000 description 1
- RCHCQUZAPRSKQL-UHFFFAOYSA-N CC(C)CC[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCCCN3CCOCC3)cnc2N)c1 Chemical compound CC(C)CC[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCCCN3CCOCC3)cnc2N)c1 RCHCQUZAPRSKQL-UHFFFAOYSA-N 0.000 description 1
- JAKRPKLKZCWVBT-UHFFFAOYSA-O CC(C)CC[n]1ncc(-c(cc2C([NH2+]c(c(F)c3F)ccc3OCCC3NCCC3)=NNNC)cnc2NC=C)c1 Chemical compound CC(C)CC[n]1ncc(-c(cc2C([NH2+]c(c(F)c3F)ccc3OCCC3NCCC3)=NNNC)cnc2NC=C)c1 JAKRPKLKZCWVBT-UHFFFAOYSA-O 0.000 description 1
- ALDWFYOLFNXPBD-UHFFFAOYSA-N CC(CC=C1OCCCN2CCOCC2)(C(F)=C1F)[n]1nnnc1-c1cc(-c2c[n](C)nc2)cnc1N Chemical compound CC(CC=C1OCCCN2CCOCC2)(C(F)=C1F)[n]1nnnc1-c1cc(-c2c[n](C)nc2)cnc1N ALDWFYOLFNXPBD-UHFFFAOYSA-N 0.000 description 1
- CKUSRLXEUYTVBE-UHFFFAOYSA-N CC(CC=C1[O](C)(CCN2CCCCC2)Oc2c-3cccc2)(C(F)=C1F)N1NNN=C1c1cc-3cnc1N Chemical compound CC(CC=C1[O](C)(CCN2CCCCC2)Oc2c-3cccc2)(C(F)=C1F)N1NNN=C1c1cc-3cnc1N CKUSRLXEUYTVBE-UHFFFAOYSA-N 0.000 description 1
- VTDIWMPYBAVEDY-UHFFFAOYSA-N CCCN1CCCCC1 Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 description 1
- RXDXJRFAANPWML-UHFFFAOYSA-N CCC[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCCN3CCCC3)cnc2N)c1 Chemical compound CCC[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCCN3CCCC3)cnc2N)c1 RXDXJRFAANPWML-UHFFFAOYSA-N 0.000 description 1
- RGSLQYTXFYFQIA-UHFFFAOYSA-O CCC[n]1ncc(-c(cc2C([NH2+]c(c(F)c3F)ccc3OCCCN3CCOCC3)=NNNC)cnc2N)c1 Chemical compound CCC[n]1ncc(-c(cc2C([NH2+]c(c(F)c3F)ccc3OCCCN3CCOCC3)=NNNC)cnc2N)c1 RGSLQYTXFYFQIA-UHFFFAOYSA-O 0.000 description 1
- WDEOAHHLUHSYIO-UHFFFAOYSA-N CCC[n]1ncc(-c2cc(-c3nnn[n]3-c(ccc(OCCCCN3CCCCC3)c3F)c3F)c(N)nc2)c1 Chemical compound CCC[n]1ncc(-c2cc(-c3nnn[n]3-c(ccc(OCCCCN3CCCCC3)c3F)c3F)c(N)nc2)c1 WDEOAHHLUHSYIO-UHFFFAOYSA-N 0.000 description 1
- LKHNPQWWFDYSNC-UHFFFAOYSA-N CN(C)c1cccc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCN3CCOCC3)cnc2N)c1 Chemical compound CN(C)c1cccc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCN3CCOCC3)cnc2N)c1 LKHNPQWWFDYSNC-UHFFFAOYSA-N 0.000 description 1
- ZWVQJRGRZCAZOC-UHFFFAOYSA-N CN(NN=C1c2cc(-c3cncnc3)cnc2N)N1c(c(F)c1F)ccc1OCCN1CCCCC1 Chemical compound CN(NN=C1c2cc(-c3cncnc3)cnc2N)N1c(c(F)c1F)ccc1OCCN1CCCCC1 ZWVQJRGRZCAZOC-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- YPSYUWALESEPCK-UHFFFAOYSA-N CN1N=C(c2cc(-c(cc3)ccc3C(NC3CC3)=O)cnc2N)N(C(C(C2F)F)=CC=C2OCCN2CCOCC2)N1 Chemical compound CN1N=C(c2cc(-c(cc3)ccc3C(NC3CC3)=O)cnc2N)N(C(C(C2F)F)=CC=C2OCCN2CCOCC2)N1 YPSYUWALESEPCK-UHFFFAOYSA-N 0.000 description 1
- OLTPUTBSJRWEHO-RLANJUCJSA-N CNC(CC1)CCC1Oc(c(F)c1F)ccc1N(/C(/c1cc(-c2c[n](C3CCOCC3)nc2)cnc1N)=N\N)N Chemical compound CNC(CC1)CCC1Oc(c(F)c1F)ccc1N(/C(/c1cc(-c2c[n](C3CCOCC3)nc2)cnc1N)=N\N)N OLTPUTBSJRWEHO-RLANJUCJSA-N 0.000 description 1
- DSQHQPGYKVBSHG-UHFFFAOYSA-N C[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCCCN3CCCC3)cnc2N)c1 Chemical compound C[n]1ncc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCCCN3CCCC3)cnc2N)c1 DSQHQPGYKVBSHG-UHFFFAOYSA-N 0.000 description 1
- VOGHQWRACVRGPZ-UHFFFAOYSA-N Cc1c[s]c(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCN3CCOCC3)cnc2N)c1 Chemical compound Cc1c[s]c(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCN3CCOCC3)cnc2N)c1 VOGHQWRACVRGPZ-UHFFFAOYSA-N 0.000 description 1
- XILZKOGFGDTYQP-UHFFFAOYSA-N Cc1c[s]c(-c(cc2C3=NNNN3c(c(F)c3F)ccc3OCCN(C)C)cnc2N)c1 Chemical compound Cc1c[s]c(-c(cc2C3=NNNN3c(c(F)c3F)ccc3OCCN(C)C)cnc2N)c1 XILZKOGFGDTYQP-UHFFFAOYSA-N 0.000 description 1
- GFMDRCVSVQBCNM-WMMMYUQOSA-N Cc1c[s]c(-c2cc(/C(/N(c(c(F)c3F)ccc3OCCCN(C)C)NC)=N/N)c(N)nc2)c1 Chemical compound Cc1c[s]c(-c2cc(/C(/N(c(c(F)c3F)ccc3OCCCN(C)C)NC)=N/N)c(N)nc2)c1 GFMDRCVSVQBCNM-WMMMYUQOSA-N 0.000 description 1
- YMOGTUWVTSTRKD-UHFFFAOYSA-N Cc1cc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCN3CCCCC3)cnc2N)c(C)cc1 Chemical compound Cc1cc(-c(cc2-c3nnn[n]3-c(c(F)c3F)ccc3OCCN3CCCCC3)cnc2N)c(C)cc1 YMOGTUWVTSTRKD-UHFFFAOYSA-N 0.000 description 1
- GUBDHYZUKXRHHK-UHFFFAOYSA-N Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OC1C(CC2)CCN2C1)c1)ncc1-c1c[s]cc1 Chemical compound Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OC1C(CC2)CCN2C1)c1)ncc1-c1c[s]cc1 GUBDHYZUKXRHHK-UHFFFAOYSA-N 0.000 description 1
- KWIJNSJNUDRVHO-UHFFFAOYSA-N Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OC1CNCCC1)c1)ncc1-c1c[s]cc1 Chemical compound Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OC1CNCCC1)c1)ncc1-c1c[s]cc1 KWIJNSJNUDRVHO-UHFFFAOYSA-N 0.000 description 1
- MRBJNQZYJDJKSN-UHFFFAOYSA-N Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCCCC1)c1)ncc1-c(cc1Cl)ccc1F Chemical compound Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCCCC1)c1)ncc1-c(cc1Cl)ccc1F MRBJNQZYJDJKSN-UHFFFAOYSA-N 0.000 description 1
- GXMBWFHXDLLDMN-UHFFFAOYSA-N Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCOCC1)c1)ncc1-c(cc1)cc(Cl)c1F Chemical compound Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCOCC1)c1)ncc1-c(cc1)cc(Cl)c1F GXMBWFHXDLLDMN-UHFFFAOYSA-N 0.000 description 1
- PFQWRGQXOQXISS-UHFFFAOYSA-N Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCOCC1)c1)ncc1-c1cc2ccccc2[s]1 Chemical compound Nc(c(-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCOCC1)c1)ncc1-c1cc2ccccc2[s]1 PFQWRGQXOQXISS-UHFFFAOYSA-N 0.000 description 1
- UYXZBBHJFJAAEW-UHFFFAOYSA-N Nc(c(-c1nnn[n]1-c(ccc(OCCN1CCCCC1)c1F)c1F)c1)ncc1-c1ccncc1 Chemical compound Nc(c(-c1nnn[n]1-c(ccc(OCCN1CCCCC1)c1F)c1F)c1)ncc1-c1ccncc1 UYXZBBHJFJAAEW-UHFFFAOYSA-N 0.000 description 1
- MCQZBXYLIPVUEP-UHFFFAOYSA-O Nc(c(C([NH2+]c(c(F)c1F)ccc1OCCN1CCOCC1)=NN=N)c1)ncc1-c1c[s]cc1 Chemical compound Nc(c(C([NH2+]c(c(F)c1F)ccc1OCCN1CCOCC1)=NN=N)c1)ncc1-c1c[s]cc1 MCQZBXYLIPVUEP-UHFFFAOYSA-O 0.000 description 1
- ZXCMVXUZQYOXKY-UHFFFAOYSA-N Nc(ncc(-c1c[s]c2c1cccc2)c1)c1-c1nnn[n]1-c(ccc(OCCN1CCOCC1)c1F)c1F Chemical compound Nc(ncc(-c1c[s]c2c1cccc2)c1)c1-c1nnn[n]1-c(ccc(OCCN1CCOCC1)c1F)c1F ZXCMVXUZQYOXKY-UHFFFAOYSA-N 0.000 description 1
- SHZRETVTTAGDNA-UHFFFAOYSA-N Nc(ncc(-c1cccnc1)c1)c1-c1nnn[n]1-c(c(F)c1F)ccc1OC1CCNCC1 Chemical compound Nc(ncc(-c1cccnc1)c1)c1-c1nnn[n]1-c(c(F)c1F)ccc1OC1CCNCC1 SHZRETVTTAGDNA-UHFFFAOYSA-N 0.000 description 1
- ZAWOFMYXLUZSRV-UHFFFAOYSA-N Nc(ncc(-c1ccncc1)c1)c1-c1nnn[n]1-c(c(F)c1F)ccc1OC1CCNCC1 Chemical compound Nc(ncc(-c1ccncc1)c1)c1-c1nnn[n]1-c(c(F)c1F)ccc1OC1CCNCC1 ZAWOFMYXLUZSRV-UHFFFAOYSA-N 0.000 description 1
- SJDUPWOSEHMPSR-UHFFFAOYSA-N Nc(ncc(-c1ccncc1)c1)c1-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCCC1 Chemical compound Nc(ncc(-c1ccncc1)c1)c1-c1nnn[n]1-c(c(F)c1F)ccc1OCCN1CCCC1 SJDUPWOSEHMPSR-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10701308P | 2008-10-21 | 2008-10-21 | |
| US61/107,013 | 2008-10-21 | ||
| PCT/US2009/061253 WO2010048131A1 (en) | 2008-10-21 | 2009-10-20 | C-met protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012506381A JP2012506381A (ja) | 2012-03-15 |
| JP2012506381A5 true JP2012506381A5 (enExample) | 2012-11-29 |
Family
ID=41381943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532324A Pending JP2012506381A (ja) | 2008-10-21 | 2009-10-20 | ｃ−ＭＥＴタンパク質キナーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8518938B2 (enExample) |
| EP (1) | EP2350045A1 (enExample) |
| JP (1) | JP2012506381A (enExample) |
| CN (1) | CN102317277A (enExample) |
| AU (1) | AU2009307770A1 (enExample) |
| CA (1) | CA2740583A1 (enExample) |
| MX (1) | MX2011004188A (enExample) |
| NZ (1) | NZ592569A (enExample) |
| WO (1) | WO2010048131A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2743134A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| DE102009024575A1 (de) | 2009-04-23 | 2010-12-23 | Fresenius Medical Care Deutschland Gmbh | Verbindungseinrichtung und Verfahren zum Konnektieren wenigstens zweier fluidführender medizinitechnischer Systeme, sowie medizintechnische Vorrichtung |
| CA2798760A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
| US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| NZ603477A (en) * | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
| MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
| WO2013049722A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN106496173A (zh) | 2011-09-30 | 2017-03-15 | 沃泰克斯药物股份有限公司 | 用于制备可用作atr激酶抑制剂的化合物的方法 |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CN108685922A (zh) | 2011-09-30 | 2018-10-23 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 |
| CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| WO2014020467A2 (en) * | 2012-07-30 | 2014-02-06 | Fresenius Kabi Oncology Ltd | Process for the preparation of pyrazole substituted aminoheteroaryl compounds |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| PT3077397T (pt) | 2013-12-06 | 2020-01-22 | Vertex Pharma | Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo |
| MX373102B (es) | 2014-06-05 | 2020-04-17 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009533327A (ja) * | 2006-03-22 | 2009-09-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤 |
| DE602008005786D1 (de) * | 2007-10-03 | 2011-05-05 | Vertex Pharma | C-met-proteinkinasehemmer |
-
2009
- 2009-10-20 JP JP2011532324A patent/JP2012506381A/ja active Pending
- 2009-10-20 EP EP09744003A patent/EP2350045A1/en not_active Withdrawn
- 2009-10-20 MX MX2011004188A patent/MX2011004188A/es not_active Application Discontinuation
- 2009-10-20 CA CA2740583A patent/CA2740583A1/en not_active Abandoned
- 2009-10-20 NZ NZ592569A patent/NZ592569A/en not_active IP Right Cessation
- 2009-10-20 AU AU2009307770A patent/AU2009307770A1/en not_active Abandoned
- 2009-10-20 CN CN2009801471841A patent/CN102317277A/zh active Pending
- 2009-10-20 WO PCT/US2009/061253 patent/WO2010048131A1/en not_active Ceased
-
2011
- 2011-04-20 US US13/090,563 patent/US8518938B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506381A5 (enExample) | ||
| JP7169412B2 (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| JP2013516393A5 (enExample) | ||
| JP6203439B2 (ja) | テトラヒドロピラニルメチル基を有するピリドン誘導体 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| WO2018022992A1 (en) | Chemokine receptor modulators and uses thereof | |
| TW201702232A (zh) | 經取代之喹唑啉化合物及其使用方法 | |
| WO2014145023A1 (en) | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2014526435A5 (enExample) | ||
| JP2010519174A5 (enExample) | ||
| JP2010523681A5 (enExample) | ||
| JP2019504826A (ja) | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| JP2010540649A5 (enExample) | ||
| JP2024543207A (ja) | 新規ｈｄａｃ阻害剤及びその治療的使用 | |
| JP2005538974A5 (enExample) | ||
| JP2012528186A5 (enExample) | ||
| CN105050602B (zh) | 作为pi3激酶抑制剂的吡啶化合物 | |
| WO2010083720A1 (zh) | 光学纯喹唑啉类化合物 | |
| JP2020521817A5 (enExample) | ||
| CN120842155A (zh) | 一类含氮杂芳基类化合物及其制备方法和应用 | |
| AU2016309356B2 (en) | Tumor therapeutic agent | |
| HK1220398B (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |